Month: October 2025

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

The paper features a comprehensive evaluation of data, including disease control rate, overall survival, immune activation, abscopal effects, tumor necrosis,...

Medical Care Technologies Inc. (OTC Pink:MDCE) Ranked #1 on InvestorHub Breakout Boards as Company Expands Across Technology and Collectibles Divisions

MESA, ARIZONA / ACCESS Newswire / October 30, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), a diversified holding company...

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company...

Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

Dr. Hurvitz is an international expert in oncology and a recognized clinical research leader with extensive experience leading clinical trials...

Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence

New collaboration provides services to streamline patient support, reduce administrative burden, and expand access to advanced TMS treatment across Elite...

error: Content is protected !!